IP Library › Granted Patent US 8,993,612

Granted Patent B2

US 8,993,612 · App. 12/899,410 · Granted Mar 31, 2015

Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer

Inventors: Meyyappan Muthuppalaniappan (Hyderabad, IN); Srikant Viswanadha (Hyderabad, IN); Kanthikiran V S Varanasi (Hyderabad, IN); Gayatri Swaroop Merikapudi (Hyderabad, IN); Swaroop Kumar V. S. Vakkalanka (La Chaux-de-Fonds, CH)

Assignee: Rhizen Pharmaceuticals SA

C07D403/12 C07D401/12 C07D471/04 C07D487/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,993,612
App. No.: 12/899,410
Granted: Mar 31, 2015
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

Claims (137)

1. A method of treating non-small cell lung cancer comprising administering to a subject in need thereof an effective amount of a compound of formula (I)

or a tautomer, N-oxide, pharmaceutically acceptable ester or pharmaceutically acceptable salt thereof, wherein

Ring Hy represents

R 1 and R 2 are the same or different and are independently selected from CH 3 , CH 2 F, CHF 2 , CF 3 , substituted or unsubstituted C (3-5) cycloalkyl, CH 2 —OR a , CH 2 —NR a R b , and COOH

with the proviso that at least one of R 1 or R 2 is C (3-5) cycloalkyl;

Ring Ar represents:

T, U and W are CH and V is CH or CF;

L 1 and L 2 together represent —NHC(═O)—;

A is absent or selected from —(CR′R″)—, O, S(═O) q , C(═X) and —NR a ;

R′ and R″ are the same or different and are independently selected from hydrogen, hydroxy, cyano, halogen, —OR a , —COOR a , —S(═O) q —R a , —NR a R b , —C(═X)—R a , substituted or unsubstituted C (1-6) alkyl group, substituted or unsubstituted C (1-6) alkenyl, substituted or unsubstituted C (1-6) alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl, or R′ and R″ may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR a and S;

each occurrence of X is independently selected from O, S and —NR a ;

Cy is a bicyclic ring selected from substituted or unsubstituted cycloalkyl group, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

each occurrence of R a and R b are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, —OR c , —S(═O) q —R c , —NR c R d , —C(═Y)—R c , —CR c R d —C(═Y)—R c , —C(═Y)—NR c R d , —NR d —C(═Y)—NR c R d , —S(═O) q —NR c R d , —NR c —S(═O) q —NR c R d , —NR c —NR c R d , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R a and R b are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR c and S;

each occurrence of R c and R d may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R c and/or R d substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S;

each occurrence of Y is selected from O, S and —NR a ; and

each occurrence of q independently represents 0, 1 or 2;

with the proviso that the compound of formula (I) is not:

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-3-(trifluoromethyl)-1H-thieno[2,3-c]pyrazole-5-carboxamide or

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-pyrazolo[1,5-a]pyrimidine-2-carboxamide.

2. The method of claim 1 , wherein the non-small cell lung cancer cells express Orai1, Orai3, Stim1, or Stim2.

3. The method of claim 1 , wherein the compound of formula (I) inhibits CRACM1/Orai1, CRACM2/Orai2, CRACM3/Orai3, or any combination thereof.

4. The method of claim 1 , wherein the compound of formula (I) inhibits Stim1, or Stim2, or any combination thereof.

5. A method of treating a patient suffering from non-small cell lung cancer comprising:

(a) determining whether the cancer cells express Orai1, Orai3, Stim1, or Stim2; and

(b) for patients having cancer cells which express Orai1, Orai3, Stim1, or Stim2, administering to the patient an effective amount of a CRAC inhibitor to treat the non-small cell lung cancer, wherein the CRAC inhibitor is a compound of formula (I)

or a tautomer, N-oxide, pharmaceutically acceptable ester or pharmaceutically acceptable salt thereof, wherein

Ring Hy represents

R 1 and R 2 are the same or different and are independently selected from CH 3 , CH 2 F, CHF 2 , CF 3 , substituted or unsubstituted C (3-5) cycloalkyl, CH 2 —OR a , CH 2 —NR a R b , and COOH

with the proviso that at least one of R 1 or R 2 is C (3-5) cycloalkyl;

Ring Ar represents:

T, U and W are CH and V is CH or CF;

L 1 and L 2 together represent —NHC(═O)—;

A is absent or selected from —(CR′R″)—, O, S(═O) q , C(═X) and —NR a ;

R′ and R″ are the same or different and are independently selected from hydrogen, hydroxy, cyano, halogen, —ORa, —COOR a , —S(═O) q —R a , —NR a R b , —C(═X)—R a , substituted or unsubstituted C (1-6) alkyl group, substituted or unsubstituted C (1-6) alkenyl, substituted or unsubstituted C (1-6) alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl, or R′ and R″ may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR a and S;

each occurrence of X is independently selected from O, S and —NR a ;

each occurrence of Y is selected from O, S and —NR a ; and

each occurrence of q independently represents 0, 1 or 2;

with the proviso that the compound of formula (I) is not:

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-3-(trifluoromethyl)-1H-thieno[2,3-c]pyrazole-5-carboxamide or

N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-pyrazolo[1,5-a]pyrimidine-2-carboxamide.

6. The method of claim 1 , wherein R 1 and R 2 are the same or different and are independently selected from CH 2 F, CHF 2 , CF 3 , and cyclopropyl with the proviso that at least one of R 1 or R 2 is cyclopropyl;

A is selected from —(CR′R″)— and —NR a ;

each occurrence of R′ and R″ are the same or different and are independently selected from hydrogen or substituted or unsubstituted C (1-6) alkyl group or R′ and R″ may be joined to form a substituted or unsubstituted saturated or unsaturated 3-6 membered ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR a and S; and

Cy is a bicyclic substituted or unsubstituted heteroaryl.

7. The method of claim 1 , wherein the compound of formula (I) is selected from:

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-1H-benzo[d]imidazole-6-carboxamide,

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-1H-benzo[d][1,2,3]triazole-6-carboxamide,

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]quinoline-6-carboxamide,

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]quinoxaline-6-carboxamide,

2-(1H-benzo[d]imidazol-1-yl)-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]acetamide,

2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]acetamide,

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(1H-indol-3-yl)acetamide,

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(imidazo[1,2-a]pyridin-2-yl)acetamide,

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(quinolin-6-yl)acetamide,

N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-2-(quinolin-6-yl)acetamide,

N-[4-(4-chloro-3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide,

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}quinoline-6-carboxamide,

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}quinoxaline-6-carboxamide,

2-(1H-benzo[d]imidazol-1-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide,

2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide,

2-(2H-benzo[d][1,2,3]triazol-2-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide,

2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide,

(S)-2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}propanamide,

2-(6-amino-9H-purin-9-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide,

N-(4-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)acetamide,

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2-(imidazo[1,2-a]pyridin-2-yl)acetamide,

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(quinolin-6-yl)acetamide,

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(quinolin-6-yl)propanamide,

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-1H-benzo[d][1,2,3]triazole-6-carboxamide,

2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}acetamide,

4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluoro-N-(quinolin-6-ylmethyl)benzamide, and

1-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-3-(quinolin-6-yl)urea,

or a tautomer, N-oxide, pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound of formula (I) is N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(quinolin-6-yl)acetamide or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound of formula (I) is 2-(1H-benzo[d]imidazol-1-yl)-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide or a pharmaceutically acceptable salt thereof.

10. The method of claim 5 , wherein the CRAC inhibitor is selected from: